Photo Credit: Myboxpra

The following is a summary of “Predictors of Boolean2.0 remission in rheumatoid arthritis identified using smart disease management system data,” published in the April 2025 issue of Scientific Reports by Zhang et al. 

Researchers conducted a retrospective study to identify factors linked to Boolean2.0 remission in patients with rheumatoid arthritis. Remission was associated with younger age, shorter disease duration, fewer tender joints, and use of methotrexate and leflunomide. 

They analyzed data from patients with RA enrolled in SSDM between January 2014 and December 2023. Demographic and clinical characteristics were compared between those who achieved Boolean2.0 remission and those who did not. Univariate and multivariate logistic regression analyses were performed to identify predictive factors. 

The results showed that among 5,004 patients, 541 (10.8%) achieved Boolean2.0 remission. The median age at diagnosis was 51.00 (42.00, 60.00) years, with 79.5% being female. The median disease duration was 26.00 (3.00, 89.00) months. Logistic regression analyses revealed that younger age (P = 0.008), shorter disease duration (P < 0.001), fewer tender joints (P < 0.001), and treatment with methotrexate (P = 0.012) and leflunomide (P = 0.001) increased the likelihood of achieving Boolean2.0 remission. 

Investigators found that younger age, shorter disease duration, fewer tender joints, and treatment with methotrexate and leflunomide were associated with an increased likelihood of achieving Boolean2.0 remission. These findings can guide clinicians in identifying high-risk patients and optimizing treatment strategies. 

Source: nature.com/articles/s41598-025-97084-2